NASDAQ:CTNM Contineum Therapeutics (CTNM) Stock Price, News & Analysis → Bigger Than NVIDIA? (From Behind the Markets) (Ad) Free CTNM Stock Alerts $16.00 0.00 (0.00%) (As of 04:31 PM ET) Add Compare Share Share Today's Range$15.30▼$16.5350-Day Range$14.09▼$17.9252-Week Range$13.27▼$18.50Volume104,392 shsAverage Volume63,742 shsMarket Capitalization$411.52 millionP/E RatioN/ADividend YieldN/APrice Target$28.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsSEC FilingsTrends Get Contineum Therapeutics alerts: Email Address Ad Weiss RatingsAre you prepared for a financial lockdown?A new kind of American dystopia is being built before our eyes, and most people have no idea what's happening. That's why I've recorded this urgent message to give you all the details on how to prepare … Including three steps to take right now.Click here to watch my video before it's too late. About Contineum Therapeutics Stock (NASDAQ:CTNM)Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.Read More CTNM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTNM Stock News HeadlinesMay 21, 2024 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for Contineum Therapeutics, Inc. Class A (CTNM)May 20, 2024 | businesswire.comContineum Therapeutics Announces Appointment of Troy Ignelzi to Board of DirectorsMay 16, 2024 | businesswire.comContineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 11, 2024 | investing.comContineum Therapeutics Inc (CTNM)May 2, 2024 | finance.yahoo.comContineum Therapeutics Announces Pricing of Initial Public OfferingSee More Headlines Receive CTNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Contineum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/16/2024Today6/17/2024Next Earnings (Estimated)8/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CTNM Previous SymbolNASDAQ:CTNM CUSIPN/A CIK1855175 Webwww.contineum-tx.com Phone(858) 333-5280FaxN/AEmployees31Year FoundedN/APrice Target and Rating Average Stock Price Target$28.00 High Stock Price Target$30.00 Low Stock Price Target$25.00 Potential Upside/Downside+75.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares25,720,000Free FloatN/AMarket Cap$411.52 million OptionableN/A BetaN/A 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Carmine N. Stengone MBA (Age 48)MS, President, CEO, Secretary & Director Comp: $790.3kMr. Peter T. Slover CPA (Age 49)Chief Financial Officer Comp: $569.7kDr. Daniel S. Lorrain Ph.D. (Age 55)Chief Science Officer Comp: $565.02kDr. Stephen L. Huhn F.A.A.P (Age 63)F.A.C.S., M.D., Chief Medical Officer & Senior VP of Clinical Development Mr. Austin Chen Ph.D.SVP & Head of ResearchMr. Michael MayberrySenior Director & Corporate ControllerMore ExecutivesKey CompetitorsEvotecNASDAQ:EVOTaro Pharmaceutical IndustriesNYSE:TAROKura OncologyNASDAQ:KURAArcus BiosciencesNYSE:RCUSAvadel PharmaceuticalsNASDAQ:AVDLView All Competitors CTNM Stock Analysis - Frequently Asked Questions Should I buy or sell Contineum Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Contineum Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CTNM shares. View CTNM analyst ratings or view top-rated stocks. What is Contineum Therapeutics' stock price target for 2024? 3 Wall Street analysts have issued 1-year price targets for Contineum Therapeutics' stock. Their CTNM share price targets range from $25.00 to $30.00. On average, they anticipate the company's stock price to reach $28.00 in the next twelve months. This suggests a possible upside of 75.0% from the stock's current price. View analysts price targets for CTNM or view top-rated stocks among Wall Street analysts. How have CTNM shares performed in 2024? Contineum Therapeutics' stock was trading at $15.40 at the start of the year. Since then, CTNM shares have increased by 3.9% and is now trading at $16.00. View the best growth stocks for 2024 here. When is Contineum Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 15th 2024. View our CTNM earnings forecast. How were Contineum Therapeutics' earnings last quarter? Contineum Therapeutics, Inc. (NASDAQ:CTNM) posted its quarterly earnings results on Thursday, May, 16th. The company reported ($3.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by $3.02. When did Contineum Therapeutics IPO? Contineum Therapeutics (CTNM) raised $110 million in an initial public offering on Friday, April 5th 2024. The company issued 6,875,000 shares at $16.00 per share. When did Contineum Therapeutics' quiet period expire? Contineum Therapeutics' quiet period expired on Wednesday, May 15th. Contineum Therapeutics had issued 6,875,000 shares in its IPO on April 5th. The total size of the offering was $110,000,000 based on an initial share price of $16.00. During Contineum Therapeutics' quiet period, insiders and any underwriters involved in the IPO were restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. How do I buy shares of Contineum Therapeutics? Shares of CTNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CTNM) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredThis AI made her leave her jobThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.